NEW YORK — Nutrition 21, Inc. (Nasdaq: NXXI) reported today results from a new clinical study that add to the growing body of clinical data demonstrating that daily supplementation with Diachrome®, a combination of chromium picolinate and biotin, can significantly reduce cardiovascular disease risk factors in people with type 2 diabetes. Findings from the randomized double-blind, placebo-controlled trial, were presented at the 2nd International Symposium on Triglycerides and HDL: Role in Cardiovascular Disease and the Metabolic Syndrome in New York, a meeting organized by the Giovanni Lorenzini Medical Foundation that is attended by both U.S. and international cardiologists and lipid specialists.
The study results presented include an analysis of subjects with type 2 diabetes who were moderately obese and taking oral antidiabetic medications. When Diachrome was added to daily treatment regimens, the atherogenic index of plasma (AIP), a predictive marker for cardiovascular disease that examines triglyceride and HDL cholesterol levels (good cholesterol), was significantly lower compared with the placebo group. The AIP in the Diachrome group dropped from 1.15 to 1.06, while it increased from 1.27 to 1.55 in the placebo group. A significant difference in triglycerides and cholesterol levels was also observed between the groups.
“These results support previous findings that Diachrome can serve as a safe and effective nutritional adjunct to medication in helping to lower triglyceride and cholesterol levels in people with type 2 diabetes,” said study investigator Jeffrey Geohas, Medical Director, Chicago Research Center. “The ability for Diachrome to reduce these risk factors is important in this population because heart disease is the leading cause of death in patients who suffer from diabetes,” said Dr. Geohas.
Nutrition 21, Inc. conducted the study in collaboration with the Chicago Research Center. “This study underscores the promise of Diachrome in helping to prevent cardiovascular disease in people with type 2 diabetes,” said Gail Montgomery, president and CEO of Nutrition 21. “As we share the wealth of clinical data demonstrating the benefits of Diachrome for people with type 2 diabetes, we anticipate that physicians will be eager to incorporate the product into clinical practice.”
Diachrome is a nutritional supplement specifically formulated for people with diabetes. It contains 600 mcg of chromium as Chromax® chromium picolinate and 2 mg of biotin. These two compounds are both Generally Recognized as Safe (GRAS) for use as ingredients in food and supplements. It is available for purchase by calling 1-866-DIACHROME or at www.diachrome.com.
About the Atherogenic Index of Plasma
AIP is an index used to measure the atherogenicity of plasma by examining the ratio of triglycerides to HDL cholesterol (good cholesterol). It identifies the risk for atherogenesis (fat build up in the arteries), particularly in diabetes patients and is recognized as a predictor for heart attack. The measurement reflects the delicate balance of metabolic interactions with the whole lipoprotein complex. Physicians currently utilize AIP in clinical practice to quantify response to therapeutic interventions.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The company markets Chromax chromium picolinate, which is the most-studied form of the essential mineral chromium. Nutrition 21 also developed Diachrome, which is available through diabetes educators or at www.diachrome.com. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at www.nutrition21.com.